A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Summary

The reason for this study is to determine if the study drug LY3471851 is safe and effective in adult participants with active ulcerative colitis (UC). The study treatment will last about 52 weeks.

Timeline

Start

2021-03-22

Primary completion

2022-08-09

Completion

2022-08-09

Outcome

Missed primary endpoint

Stopped (Enrollment): “Study terminated due to enrollment futility.”

registry analysis (superiority test); Placebo (Induction Treatment Period) vs Low Dose LY3471851 (Induction Treatment Period); p = 0.750; NCT04677179 ↗

registry analysis (superiority test); Placebo (Induction Treatment Period) vs High Dose LY3471851 (Induction Treatment Period); p = 0.838; NCT04677179 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rezpegaldesleukin	Protein / enzyme biologic	—	Subcutaneous

Indications